NO20021719L - 6-position substituted indolines, preparation and use thereof as a drug - Google Patents

6-position substituted indolines, preparation and use thereof as a drug

Info

Publication number: NO20021719L
Authority: NO; Norway
Prior art keywords: drug; preparation; position substituted; substituted indolines; indolines
Prior art date: 1999-10-13

Application number

NO20021719A

Other languages

Norwegian (no)

Other versions

NO20021719D0 (en

NO322746B1 (en

Inventor

Armin Heckel

Gerald Juergen Roth

Rainer Walter

Jacobus Van Meel

Norbert Redemann

Ulrike Tontsch-Grunt

Walter Spevak

Frank Hilberg

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-13

Filing date

2002-04-11

Publication date

2002-04-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20021719(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-10-13 Priority claimed from DE19949208A external-priority patent/DE19949208A1/en

2000-08-31 Priority claimed from DE2000142696 external-priority patent/DE10042696A1/en

2002-04-11 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2002-04-11 Publication of NO20021719D0 publication Critical patent/NO20021719D0/en

2002-04-11 Publication of NO20021719L publication Critical patent/NO20021719L/en

2006-12-04 Publication of NO322746B1 publication Critical patent/NO322746B1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Transplantation (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20021719A 1999-10-13 2002-04-11 Indolines, substituted at the 6-position, and pharmaceutical composition, as well as the use and preparation thereof. NO322746B1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19949208A DE19949208A1 (en)	1999-10-13	1999-10-13	New 3-(amino-methylene)-2-indolinone derivatives are kinase inhibitors and cell proliferation inhibitors useful e.g. for treating tumors, metastasis, rheumatoid arthritis or psoriasis
DE2000142696 DE10042696A1 (en)	2000-08-31	2000-08-31	New 3-(amino-methylene)-2-indolinone derivatives are kinase inhibitors and cell proliferation inhibitors useful e.g. for treating tumors, metastasis, rheumatoid arthritis or psoriasis
PCT/EP2000/009867 WO2001027081A1 (en)	1999-10-13	2000-10-09	6-position substituted indoline, production and use thereof as a medicament

Publications (3)

Publication Number	Publication Date
NO20021719D0 NO20021719D0 (en)	2002-04-11
NO20021719L true NO20021719L (en)	2002-04-11
NO322746B1 NO322746B1 (en)	2006-12-04

Family

ID=26006858

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20021719A NO322746B1 (en)	1999-10-13	2002-04-11	Indolines, substituted at the 6-position, and pharmaceutical composition, as well as the use and preparation thereof.
NO2015009C NO2015009I1 (en)	1999-10-13	2015-03-18	Nintedanib, tautomers and salts thereof, in particular Nintedanib and physiologically acceptable salts thereof, in particular Nintedanib esilate; 3-Z- [1- (4- (N - ((4-methylpiperazin-1-yl) -methylcarbonyl) -N-methylamino) -anilino) -1-phenylmethylene] -6-methoxycarbonyl-2-indolinone - See among other claims 1, 2, 5 (t) and 6 of the basic patent
NO2023033C NO2023033I1 (en)	1999-10-13	2023-09-05	Nintedanib

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO2015009C NO2015009I1 (en)	1999-10-13	2015-03-18	Nintedanib, tautomers and salts thereof, in particular Nintedanib and physiologically acceptable salts thereof, in particular Nintedanib esilate; 3-Z- [1- (4- (N - ((4-methylpiperazin-1-yl) -methylcarbonyl) -N-methylamino) -anilino) -1-phenylmethylene] -6-methoxycarbonyl-2-indolinone - See among other claims 1, 2, 5 (t) and 6 of the basic patent
NO2023033C NO2023033I1 (en)	1999-10-13	2023-09-05	Nintedanib

Country Status (43)

Country	Link
EP (2)	EP1224170B9 (en)
JP (2)	JP4021664B2 (en)
KR (2)	KR100835546B1 (en)
CN (1)	CN100455568C (en)
AR (1)	AR026036A1 (en)
AT (1)	ATE439342T1 (en)
AU (1)	AU781939B2 (en)
BE (1)	BE2015C018I2 (en)
BG (1)	BG65983B1 (en)
BR (1)	BRPI0014735B8 (en)
CA (1)	CA2387013C (en)
CO (1)	CO5261488A1 (en)
CY (2)	CY1110067T1 (en)
CZ (1)	CZ301073B6 (en)
DE (1)	DE50015711D1 (en)
DK (1)	DK1224170T5 (en)
EA (1)	EA006080B1 (en)
EE (1)	EE05427B1 (en)
EG (1)	EG25931A (en)
ES (1)	ES2331459T3 (en)
FR (1)	FR15C0024I2 (en)
HK (1)	HK1052505B (en)
HR (1)	HRP20020306B1 (en)
HU (2)	HU230416B1 (en)
IL (2)	IL148756A0 (en)
LT (1)	LTC1224170I2 (en)
LU (1)	LU92681I2 (en)
ME (1)	MEP45408A (en)
MX (1)	MXPA02002799A (en)
MY (1)	MY127956A (en)
NL (1)	NL300725I2 (en)
NO (3)	NO322746B1 (en)
NZ (1)	NZ518489A (en)
PE (1)	PE20010671A1 (en)
PL (1)	PL207445B1 (en)
PT (1)	PT1224170E (en)
RS (1)	RS51013B (en)
SA (1)	SA01210704B1 (en)
SI (1)	SI1224170T1 (en)
SK (1)	SK287312B6 (en)
TW (1)	TWI268922B (en)
UA (1)	UA75054C2 (en)
WO (1)	WO2001027081A1 (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19816624A1 (en) *	1998-04-15	1999-10-21	Boehringer Ingelheim Pharma	Novel substituted indolinones, their preparation and their use as pharmaceuticals
EP1415987B1 (en)	2000-10-20	2007-02-28	Eisai R&D Management Co., Ltd.	Nitrogenous aromatic ring compounds as anti cancer agents
US6638965B2 (en)	2000-11-01	2003-10-28	Boehringer Ingelheim Pharma Kg	Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (en)	2001-04-06	2002-10-10	Boehringer Ingelheim Pharma	Indolinones substituted in the 6-position, their preparation and their use as medicaments
US7678805B2 (en)	2001-06-29	2010-03-16	Ab Science	Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
US7727731B2 (en)	2001-06-29	2010-06-01	Ab Science	Potent, selective and non toxic c-kit inhibitors
JP2004536097A (en) *	2001-06-29	2004-12-02	アブサイエンス	Uses of tyrosine kinase inhibitors to treat autoimmune diseases
EP1401415B1 (en)	2001-06-29	2006-06-21	AB Science	Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases
US20030091974A1 (en) *	2001-06-29	2003-05-15	Alain Moussy	Method for screening compounds capable of depleting mast cells
CA2452371A1 (en)	2001-06-29	2003-01-09	Ab Science	Use of tyrosine kinase inhibitors for treating allergic diseases
US20030225152A1 (en) *	2001-09-27	2003-12-04	Andrews Steven W.	3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
US6797825B2 (en)	2001-12-13	2004-09-28	Abbott Laboratories	Protein kinase inhibitors
RU2316554C2 (en)	2001-12-27	2008-02-10	Тереванс, Инк.	Derivatives of indoline used as protein kinase inhibitors
SE0302546D0 (en)	2003-09-24	2003-09-24	Astrazeneca Ab	New compounds
ITBO20020198A1 (en) *	2002-04-12	2003-10-13	Univ Bologna	DERIVATIVES 2, 5 BIS DIAMMINO 1, 4 BENZOCHENIONIC USEFUL FOR THE TREATMENT OF ALZHEIMER DISEASE, METHOD FOR THEIR PREPARATION AND
US7514468B2 (en)	2002-07-23	2009-04-07	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en)	2002-07-23	2007-01-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (en)	2002-07-24	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-Z- [1- (4- (N - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl- 2-indolinone monoethanesulfonate and its use as a medicament
US20040204458A1 (en)	2002-08-16	2004-10-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (en) *	2002-08-16	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound
US7148249B2 (en) *	2002-09-12	2006-12-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (en) *	2002-11-27	2012-02-22	アラーガン、インコーポレイテッド	Kinase inhibitors for the treatment of diseases
US20050043233A1 (en)	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2005044788A1 (en)	2003-11-11	2005-05-19	Eisai Co., Ltd.	Urea derivative and process for producing the same
SE0401790D0 (en) *	2004-07-07	2004-07-07	Forskarpatent I Syd Ab	Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) *	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
US8772269B2 (en)	2004-09-13	2014-07-08	Eisai R&D Management Co., Ltd.	Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP1797877A4 (en)	2004-09-13	2010-12-15	Eisai Co Ltd	Joint use of sulfonamide based compound with angiogenesis inhibitor
AU2005283422C1 (en)	2004-09-17	2017-02-02	Eisai R & D Management Co., Ltd.	Medicinal composition
PE20060777A1 (en) *	2004-12-24	2006-10-06	Boehringer Ingelheim Int	INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
EP2281901B1 (en)	2005-08-02	2013-11-27	Eisai R&D Management Co., Ltd.	Anti-tumour pharmaceutical composition with angiogenesis inhibitors
WO2007057397A1 (en) *	2005-11-15	2007-05-24	Boehringer Ingelheim International Gmbh	Treatment of cancer
WO2007136103A1 (en)	2006-05-18	2007-11-29	Eisai R & D Management Co., Ltd.	Antitumor agent for thyroid cancer
EP1870400A1 (en) *	2006-06-08	2007-12-26	Boehringer Ingelheim Pharma GmbH & Co. KG	Salts and crystalline salt forms of an 2-indolinone derivative
WO2008026748A1 (en)	2006-08-28	2008-03-06	Eisai R & D Management Co., Ltd.	Antitumor agent for undifferentiated gastric cancer
EP2119707B1 (en)	2007-01-29	2015-01-14	Eisai R&D Management Co., Ltd.	Composition for treatment of undifferentiated-type of gastric cancer
US20100184747A1 (en) *	2007-06-12	2010-07-22	Boehringer Ingelheim International Gmbh	Indoline derivatives and their use in treating disease-states such as cancer
ES2435454T3 (en)	2007-06-21	2013-12-19	Janssen Pharmaceutica, N.V.	Indolin-2-one and aza-indolin-2-one
CA2704000C (en)	2007-11-09	2016-12-13	Eisai R&D Management Co., Ltd.	Combination of anti-angiogenic substance and anti-tumor platinum complex
PE20091445A1 (en) *	2007-12-03	2009-10-19	Boehringer Ingelheim Int	INDOLINONE DERIVATIVES AND PROCEDURE FOR ITS MANUFACTURE
ES2658091T3 (en) *	2007-12-03	2018-03-08	Boehringer Ingelheim International Gmbh	Procedure for the manufacture of an indolinone derivative
SI2985025T1 (en)	2008-06-06	2018-04-30	Boehringer Ingelheim International Gmbh	Pharmaceutical combination
TW201011002A (en)	2008-07-29	2010-03-16	Boehringer Ingelheim Int	New compounds
EP2387401A1 (en)	2009-01-14	2011-11-23	Boehringer Ingelheim International GmbH	Method for treating colorectal cancer
US8802384B2 (en)	2009-03-12	2014-08-12	Boehringer Ingelheim International Gmbh	Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (en)	2009-03-24	2010-09-30	Life & Brain Gmbh	Promotion of neuronal integration in neural stem cell grafts
EP2429520A1 (en)	2009-05-14	2012-03-21	Boehringer Ingelheim International GmbH	New combination therapy in treatment of oncological and fibrotic diseases
ES2564797T3 (en)	2009-08-19	2016-03-29	Eisai R&D Management Co., Ltd.	Pharmaceutical composition containing a quinoline derivative
US20120107304A1 (en)	2010-04-27	2012-05-03	Boehringer Ingelheim International Gmbh	Combination therapy in treatment of oncological and fibrotic diseases
RU2560683C2 (en)	2010-06-25	2015-08-20	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Anticancer agent involving combinations of kinase inhibitory compounds
WO2012068441A2 (en)	2010-11-19	2012-05-24	Ratiopharm Gmbh	Intedanib salts and solid state forms thereof
MX2013009931A (en)	2011-04-18	2013-10-01	Eisai R&D Man Co Ltd	Therapeutic agent for tumor.
ES2705950T3 (en)	2011-06-03	2019-03-27	Eisai R&D Man Co Ltd	Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
DK2807160T3 (en)	2012-01-26	2019-10-14	Angion Biomedica Corp	ANTIFIBROTIC COMPOUNDS AND APPLICATIONS THEREOF
WO2014071419A2 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
HK1214830A1 (en)	2012-11-05	2016-08-05	Foundation Medicine, Inc.	Novel ntrk1 fusion molecules and uses thereof
WO2014086102A1 (en)	2012-12-06	2014-06-12	山东亨利医药科技有限责任公司	Indole full ketone derivative used as tyrosine-kinase inhibitor
WO2014098176A1 (en)	2012-12-21	2014-06-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	Amorphous form of quinoline derivative, and method for producing same
WO2014113729A2 (en)	2013-01-18	2014-07-24	Foundation Mecicine, Inc.	Methods of treating cholangiocarcinoma
US20140350022A1 (en)	2013-05-10	2014-11-27	Boehringer Ingelheim International Gmbh	Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
RU2658601C2 (en)	2013-05-14	2018-06-21	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN104003925B (en) *	2013-06-05	2016-03-30	四川大学	Indolinone compound or its derivative and use thereof
WO2015009889A1 (en) *	2013-07-18	2015-01-22	Concert Pharmaceuticals, Inc.	Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
JP6799201B2 (en)	2013-07-31	2020-12-16	アヴァリンファーマインク．	Aerosol Tyrosine Kinase Inhibitor Compounds and Their Use
ES2926687T3 (en)	2014-08-28	2022-10-27	Eisai R&D Man Co Ltd	Highly pure quinoline derivative and method for its production
CN104262232B (en) *	2014-09-09	2016-05-04	苏州明锐医药科技有限公司	The preparation method of Ni Taidani
RS65049B1 (en)	2015-02-25	2024-02-29	Eisai R&D Man Co Ltd	Method for suppressing bitterness of quinoline derivative
AU2015384801B2 (en)	2015-03-04	2022-01-06	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2016178064A1 (en)	2015-05-06	2016-11-10	Suven Life Sciences Limited	Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499B (en) *	2015-06-05	2017-03-08	北京康立生医药技术开发有限公司	One kettle way prepares the synthetic method of Nintedanib
ES2971096T3 (en)	2015-06-06	2024-06-03	Cloudbreak Therapeutics Llc	Compositions and methods for treating therygium
CA2988707C (en)	2015-06-16	2023-10-10	Eisai R&D Management Co., Ltd.	Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN105126909B (en) *	2015-07-13	2018-01-23	淮海工学院	Application of the immobilized palladium catalyst in the synthesis of the nitrobenzene methyl of 4 phenylacetylene base 3
CZ308695B6 (en)	2015-07-29	2021-03-03	Zentiva, K.S.	Process for preparing methyl (Z) -3 - [[4- [methyl [2- (4-methyl-1-piperazinyl) acetyl] amino] phenyl] amino] phenylmethylene) -oxindole-6-carboxylate (intedanib, nintedanib)
CN106467500A (en) *	2015-08-14	2017-03-01	廊坊百瑞化工有限公司	A kind of one pot synthesis synthesize the new method of Nintedanib key intermediate
ES2887426T3 (en)	2015-08-20	2021-12-22	Eisai R&D Man Co Ltd	Lenvatinib combined with etoposide and ifosfamide for use in treating a tumor
WO2017109513A1 (en)	2015-12-24	2017-06-29	Respivert Limited	Indolinones compounds and their use in the treatment of fibrotic diseases
CZ2016104A3 (en)	2016-02-24	2017-09-06	Zentiva, K.S.	Crystalline modifications of methyl (3Z)-3- {[(4-{methyl[(4-methylpiperazin-1yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2oxo-2,3-dihydro-1H-indole-6-carboxylate and the methods of their preparation
WO2017153748A1 (en)	2016-03-08	2017-09-14	Respivert Limited	Indole derivatives and their use as protein kinase inhibitors
US20190160054A1 (en)	2016-04-13	2019-05-30	Boehringer Ingelheim International Gmbh	Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en)	2016-05-19	2017-11-22	Boehringer Ingelheim International Gmbh	Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
JP2019522638A (en)	2016-05-27	2019-08-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Use of ECM biomarkers to determine initiation of treatment with nintedanib and pirfenidone
US20190275033A1 (en)	2016-06-01	2019-09-12	Boehringer Ingelheim International Gmbh	Use of ecm biomarkers for determining the treatment onset with nintedanib and pirfenidone
KR20240052865A (en)	2016-06-02	2024-04-23	에이디에스 테라퓨틱스 엘엘씨	Compositions and methods of using nintedanib for improving glaucoma surgery success
MX395539B (en)	2016-07-29	2025-03-25	Oncternal Therapeutics Inc	USES OF INDOLINONE COMPOUNDS
CN106748961A (en) *	2016-11-30	2017-05-31	瑞阳制药有限公司	The impurity compound of Nintedanib, preparation method, using and its detection method
CN106748960A (en) *	2016-11-30	2017-05-31	瑞阳制药有限公司	The potential impurity compound of Nintedanib, preparation method, using and its detection method
CN110062625A (en)	2016-12-12	2019-07-26	勃林格殷格翰国际有限公司	Nintedanib by giving the method for treating interstitial lung disease with Ao Dateluo altogether
JP6581320B2 (en)	2017-02-08	2019-09-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	Pharmaceutical composition for tumor treatment
JP2020512364A (en)	2017-03-28	2020-04-23	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Nintedanib for use in a method of treating muscular dystrophy
RU2019134940A (en)	2017-05-16	2021-06-16	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	TREATMENT OF HEPATOCELLULAR CARCINOMA
EP3700529B1 (en)	2017-10-23	2025-07-09	Boehringer Ingelheim International GmbH	New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
WO2019097112A1 (en)	2017-11-17	2019-05-23	Fermion Oy	Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib
JP7061310B2 (en) *	2018-04-05	2022-04-28	国立大学法人大分大学	Pharmaceuticals for the prevention and treatment of chronic fatty diseases
CN108358827A (en) *	2018-05-07	2018-08-03	日照市普达医药科技有限公司	It is a kind of to treat psoriasic 2- oxo-indoles analog derivative and preparation method thereof
KR20210013574A (en)	2018-05-25	2021-02-04	클라우드브레이크 테라퓨틱스, 엘엘씨	Composition for treating ocular congestion and method for treating ocular congestion using the same
WO2020070331A1 (en) *	2018-10-05	2020-04-09	Ichnos Sciences S.A.	Indolinone compounds for use as map4k1 inhibitors
WO2021198253A1 (en)	2020-04-01	2021-10-07	Boehringer Ingelheim International Gmbh	Use of biomarkers in the treatment of fibrotic conditions
CN111848490B (en) *	2020-08-24	2021-09-24	江西国药有限责任公司	A kind of preparation method of high-purity nintedanib ethanesulfonate
CN112574094B (en) *	2020-12-14	2022-07-01	成都大学	Indolone derivatives and pharmaceutical use thereof
EP4541368A3 (en)	2021-01-25	2025-07-02	Nibec Co., Ltd.	Peptide for preventing and treating fibrosis
EP4098246A1 (en)	2021-05-31	2022-12-07	Lotus Pharmaceutical Co., Ltd.	Formulation of nintedanib
CN115703758B (en) *	2021-08-12	2024-03-26	中国医学科学院药物研究所	Compounds used as kinase inhibitors, preparation method and application thereof
WO2024037982A1 (en)	2022-08-16	2024-02-22	Boehringer Ingelheim International Gmbh	Pharmaceutical formulations of nintedanib for intraocular use
TWI857798B (en) *	2023-09-28	2024-10-01	國立臺灣大學	Indoline derivatives for treatment and/or prevention of tumor or cell proliferative and fibrosis diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL96047C (en) *	1956-06-08
JP2742333B2 (en) *	1994-05-06	1998-04-22	アルコンラボラトリーズ，インコーポレイテッド	Use of vitamin E tocopheryl derivatives in ophthalmic compositions
US5880141A (en) *	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
EP0815859B1 (en) *	1996-01-17	2003-06-18	Taiho Pharmaceutical Company Limited	Intimal thickening inhibitors
GB9718913D0 (en) *	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
DE19815020A1 (en) *	1998-04-03	1999-10-07	Boehringer Ingelheim Pharma	New substituted indolinones, their production and their use as medicines
DE19816624A1 (en) *	1998-04-15	1999-10-21	Boehringer Ingelheim Pharma	Novel substituted indolinones, their preparation and their use as pharmaceuticals
DE19824922A1 (en)	1998-06-04	1999-12-09	Boehringer Ingelheim Pharma	Novel substituted indolinones, their preparation and their use as pharmaceuticals
GB9904933D0 (en) *	1999-03-04	1999-04-28	Glaxo Group Ltd	Compounds

2000
- 2000-09-10 UA UA2002053890A patent/UA75054C2/en unknown
- 2000-10-09 DE DE50015711T patent/DE50015711D1/en not_active Expired - Lifetime
- 2000-10-09 RS YUP-266/02A patent/RS51013B/en unknown
- 2000-10-09 SI SI200031039T patent/SI1224170T1/en unknown
- 2000-10-09 IL IL14875600A patent/IL148756A0/en active IP Right Grant
- 2000-10-09 HU HU0204587A patent/HU230416B1/en active Protection Beyond IP Right Term
- 2000-10-09 WO PCT/EP2000/009867 patent/WO2001027081A1/en not_active Ceased
- 2000-10-09 ES ES00971347T patent/ES2331459T3/en not_active Expired - Lifetime
- 2000-10-09 JP JP2001530102A patent/JP4021664B2/en not_active Expired - Lifetime
- 2000-10-09 PL PL355433A patent/PL207445B1/en not_active IP Right Cessation
- 2000-10-09 EE EEP200200197A patent/EE05427B1/en active Protection Beyond IP Right Term
- 2000-10-09 KR KR1020027004701A patent/KR100835546B1/en not_active Expired - Lifetime
- 2000-10-09 EA EA200200380A patent/EA006080B1/en not_active IP Right Cessation
- 2000-10-09 BR BRPI0014735-4 patent/BRPI0014735B8/en active IP Right Grant
- 2000-10-09 HR HR20020306A patent/HRP20020306B1/en not_active IP Right Cessation
- 2000-10-09 NZ NZ518489A patent/NZ518489A/en not_active IP Right Cessation
- 2000-10-09 CA CA002387013A patent/CA2387013C/en not_active Expired - Lifetime
- 2000-10-09 CZ CZ20021410A patent/CZ301073B6/en unknown
- 2000-10-09 EP EP00971347.0A patent/EP1224170B9/en not_active Expired - Lifetime
- 2000-10-09 AT AT00971347T patent/ATE439342T1/en active
- 2000-10-09 EP EP09164507A patent/EP2157081A1/en not_active Withdrawn
- 2000-10-09 KR KR1020077017807A patent/KR100857734B1/en not_active Expired - Lifetime
- 2000-10-09 DK DK00971347.0T patent/DK1224170T5/en active
- 2000-10-09 AU AU10233/01A patent/AU781939B2/en not_active Expired
- 2000-10-09 CN CNB008158681A patent/CN100455568C/en not_active Expired - Lifetime
- 2000-10-09 SK SK646-2002A patent/SK287312B6/en not_active IP Right Cessation
- 2000-10-09 HK HK03104649.4A patent/HK1052505B/en not_active IP Right Cessation
- 2000-10-09 PT PT00971347T patent/PT1224170E/en unknown
- 2000-10-09 MX MXPA02002799A patent/MXPA02002799A/en active IP Right Grant
- 2000-10-09 ME MEP-454/08A patent/MEP45408A/en unknown
- 2000-10-11 MY MYPI20004762A patent/MY127956A/en unknown
- 2000-10-11 EG EG2000101293A patent/EG25931A/en active
- 2000-10-11 PE PE2000001088A patent/PE20010671A1/en not_active IP Right Cessation
- 2000-10-12 TW TW089121320A patent/TWI268922B/en not_active IP Right Cessation
- 2000-10-12 CO CO00077925A patent/CO5261488A1/en not_active Application Discontinuation
- 2000-10-13 AR ARP000105394A patent/AR026036A1/en active IP Right Grant
2001
- 2001-02-06 SA SA01210704A patent/SA01210704B1/en unknown
2002
- 2002-03-19 IL IL148756A patent/IL148756A/en active Protection Beyond IP Right Term
- 2002-04-05 BG BG106587A patent/BG65983B1/en unknown
- 2002-04-11 NO NO20021719A patent/NO322746B1/en active Protection Beyond IP Right Term
2007
- 2007-08-15 JP JP2007211755A patent/JP2007302697A/en active Pending
2009
- 2009-11-06 CY CY20091101152T patent/CY1110067T1/en unknown
2015
- 2015-03-13 CY CY2015009C patent/CY2015009PI1/en unknown
- 2015-03-16 LT LTPA2015015C patent/LTC1224170I2/en unknown
- 2015-03-16 NL NL300725C patent/NL300725I2/en unknown
- 2015-03-16 FR FR15C0024C patent/FR15C0024I2/en active Active
- 2015-03-16 LU LU92681C patent/LU92681I2/en unknown
- 2015-03-16 BE BE2015C018C patent/BE2015C018I2/fr unknown
- 2015-03-18 NO NO2015009C patent/NO2015009I1/en unknown
2016
- 2016-05-13 HU HUS1600022C patent/HUS1600022I1/en unknown
2023
- 2023-09-05 NO NO2023033C patent/NO2023033I1/en unknown

Also Published As

Publication number	Publication date
HRP20020306A2 (en)	2003-10-31
IL148756A (en)	2007-10-31
CY2015009PI2 (en)	2016-12-14
DK1224170T5 (en)	2018-01-22
BRPI0014735A (en)	2002-07-16
AR026036A1 (en)	2002-12-26
BG65983B1 (en)	2010-08-31
JP2003511441A (en)	2003-03-25
EP2157081A1 (en)	2010-02-24
PT1224170E (en)	2009-10-01
NO20021719D0 (en)	2002-04-11
KR100835546B1 (en)	2008-06-09
NO322746B1 (en)	2006-12-04
EA006080B1 (en)	2005-08-25
KR20020038949A (en)	2002-05-24
AU781939B2 (en)	2005-06-23
DK1224170T3 (en)	2009-12-07
EA200200380A1 (en)	2002-10-31
BE2015C018I2 (en)	2019-10-23
SI1224170T1 (en)	2009-12-31
HU230416B1 (en)	2016-05-30
HUP0204587A2 (en)	2003-05-28
HUP0204587A3 (en)	2004-07-28
EE200200197A (en)	2003-06-16
SA01210704B1 (en)	2006-12-05
SK6462002A3 (en)	2002-08-06
EP1224170B9 (en)	2017-11-22
ES2331459T3 (en)	2010-01-05
BG106587A (en)	2003-01-31
WO2001027081A1 (en)	2001-04-19
EP1224170B1 (en)	2009-08-12
TWI268922B (en)	2006-12-21
PL207445B1 (en)	2010-12-31
PL355433A1 (en)	2004-04-19
RS51013B (en)	2010-10-31
HUS1600022I1 (en)	2017-02-28
EG25931A (en)	2012-10-24
LU92681I9 (en)	2019-01-03
KR100857734B1 (en)	2008-09-10
CO5261488A1 (en)	2003-03-31
NO2015009I2 (en)	2015-03-18
IL148756A0 (en)	2002-09-12
EP1224170A1 (en)	2002-07-24
HK1052505A1 (en)	2003-09-19
CN100455568C (en)	2009-01-28
LTPA2015015I1 (en)	2015-04-27
HRP20020306B1 (en)	2010-09-30
CY1110067T1 (en)	2015-01-14
PE20010671A1 (en)	2001-06-28
BRPI0014735B8 (en)	2021-07-06
NO2015009I1 (en)	2015-03-30
FR15C0024I2 (en)	2016-08-26
UA75054C2 (en)	2006-03-15
CA2387013A1 (en)	2001-04-19
CN1391557A (en)	2003-01-15
NL300725I2 (en)	2017-07-13
JP2007302697A (en)	2007-11-22
AU1023301A (en)	2001-04-23
CA2387013C (en)	2009-12-29
SK287312B6 (en)	2010-06-07
LU92681I2 (en)	2015-05-18
YU26602A (en)	2004-11-25
MEP45408A (en)	2011-02-10
HK1052505B (en)	2009-06-26
MXPA02002799A (en)	2003-02-27
DE50015711D1 (en)	2009-09-24
CZ301073B6 (en)	2009-10-29
NO2023033I1 (en)	2023-09-05
BRPI0014735B1 (en)	2012-07-10
EE05427B1 (en)	2011-06-15
CZ20021410A3 (en)	2002-07-17
FR15C0024I1 (en)	2015-04-17
NZ518489A (en)	2005-05-27
MY127956A (en)	2007-01-31
JP4021664B2 (en)	2007-12-12
KR20070095996A (en)	2007-10-01
ATE439342T1 (en)	2009-08-15
CY2015009PI1 (en)	2016-12-14
LTC1224170I2 (en)	2023-11-10

Publication	Publication Date	Title
NO20021719L (en)	2002-04-11	6-position substituted indolines, preparation and use thereof as a drug
DK1218341T3 (en)	2005-12-12	Sulfonylcarboxamide derivatives, process for their preparation and their use as a drug
NO20012567D0 (en)	2001-05-25	Azepinoindole derivatives, preparation and use thereof
NO20021689L (en)	2002-05-30	5-membered heterocyclic derivatives, their preparation and use as drugs
DK1095025T3 (en)	2003-04-07	Benzimidazoles, their preparation and their use as drugs
DK1953162T3 (en)	2012-09-10	Xanthine derivatives, their preparation and their use as a drug.
DK1083171T3 (en)	2004-08-09	Pyrazoline derivatives, their preparation and use as drugs
NO20025879D0 (en)	2002-12-06	Acylphenylurea derivatives, process for their preparation and their use as a drug
NO20006138D0 (en)	2000-12-01	Substituted indolinones, preparation and use thereof as drugs
NO20011503D0 (en)	2001-03-23	Indeno-, naphtho- and benzocyclohepta-dihydrotiazole derivatives, their preparation and use as anorectic drugs
NO20014702L (en)	2001-09-27	Diaryl derivatives and their use as drugs
NO20005146D0 (en)	2000-10-13	Thienylazolylalkoxyethanamines, their preparation and their use as drugs
NO20024749D0 (en)	2002-10-02	Indolin-2-one derivatives, their preparation and use as ocytocin receptor ligands
DK1161434T3 (en)	2003-05-26	Pyridopyranoazepine derivatives, their preparation and therapeutic use
DK1230230T3 (en)	2003-12-15	Derivatives of indeno-dihydrothiazole, its preparation and use as anorectic drugs
NO20023146L (en)	2002-06-28	Substituted phenyl-piperazine derivatives, their preparation and use
DK1043307T3 (en)	2003-09-22	3-Amino-3-arylpropan-1-ol derivatives, their preparation and use
DK1523473T3 (en)	2013-06-03	Indoline derivatives substituted at position 6, their preparation and use as a drug.
NO20010219L (en)	2001-03-15	Polycyclic thiazolidin-2-ylidenamines, process for their preparation and their use as a drug
DK1157020T3 (en)	2003-01-27	Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-2-benzazocin-10-ols, processes for their preparation and their use as a drug
NO20001782L (en)	2000-10-09	3-Amino-3-arylpropan-1-ol derivatives, their preparation and use
DK1235809T3 (en)	2004-03-15	Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as drugs
NO20015617L (en)	2002-01-15	Spiroimidazole derivatives, their preparation, their use and pharmaceutical preparations including such derivatives
NO20020404D0 (en)	2002-01-25	Streptogramin derivatives, their production and compounds thereof
IS6391A (en)	2002-05-21	2-Arylquinoline derivatives, preparation and therapeutic use thereof

Legal Events

Date	Code	Title	Description
2015-03-30	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: VARGATEF, NINTEDANIB; REG. NO/DATE: EU/1/14/954-001-004 20141201 Spc suppl protection certif: 2015009 Filing date: 20150318
2017-01-09	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: NINTEDANIB, TAUTOMERE OG SALTER DERAV, SPESIELT NINTEDANIB OG FYSIOLOGISKE AKSEPTABLE SALTER DERAV, SPESIELT NINTEDANIB ESILAT; REG. NO/DATE: EU/1/14/954-001-004 20141201 Spc suppl protection certif: 2015009 Filing date: 20150318 Extension date: 20251009
2020-11-09	MK1K	Patent expired
2023-09-18	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: NINTEDANIB; REG. NO/DATE: EU/1/14/954-001-004 20141201 Spc suppl protection certif: 2023033 Filing date: 20230905